Veradermics MANE
NYSE MANE
$148.63 +4.88 (+3.39%)
At close: Nov 10, 2026 · 4:00 PM EST

Veradermics (MANE) Return on Assets [ROA] (2026)

Updated

Veradermics (MANE) reported Return on Assets [ROA] of -12.88% for Q2 2026.

Analysis

Veradermics (MANE) Return on Assets [ROA] (2026) Analysis & Trends

For FY2025, Veradermics posted Return on Assets [ROA] of -67.25%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 19.00%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.08%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 7.32%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 1.87%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.36%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 9.80%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -7.67%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 2.00%
10 Veradermics 822.06 Mn -1.33 Bn - -11.84%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -11.84%
Jun 30, 2026 -15.30%
Mar 31, 2026 -31.04%
API Access

Veradermics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=MANE&period=max&api_key=YOUR_API_KEY